GILEAD SCIENCES SL

Six generic drugmakers, including Dr. Reddy’s, Hetero, and Mylan, signed non-exclusive, royalty-free licensing agreements with Gilead Sciences to manufacture and market generic lenacapavir in 120 high-incidence countries. Lenacapavir, approved for treating multidrug-resistant HIV-1, is under investigation for HIV prevention but not yet globally approved.

The European Commission approves Ipsen's IQIRVO (elafibranor) for primary biliary cholangitis, the first new therapy in the EU in a decade. Other companies, including CymaBay, Zydus, and GlaxoSmithKline, are preparing to enter the market. The approval is based on the Phase III ELATIVE trial, showing a 47% clinical benefit of IQIRVO combined with UDCA. Additionally, Gilead Sciences' LIVDELZI (seladelpar) received FDA accelerated approval for PBC.

Gilead Sciences partners with six pharma companies to produce generic lenacapavir for HIV prevention and treatment, aiming to sell in 120 resource-limited countries, responding to HIV advocacy groups' calls for affordability, though some advocates feel the move is insufficient.

Hetero and Dr Reddy’s sign non-exclusive, royalty-free licensing agreement with Gilead Sciences to manufacture and distribute lenacapavir, an HIV treatment drug, in 120 low- and lower-middle-income countries, including India. Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is currently under investigation for HIV prevention. The agreement aims to make the drug accessible at affordable costs, with Indian generic manufacturers potentially producing it for $100 per person per year.

Dr Reddy's Laboratories partners with Gilead Sciences for the manufacture and commercialisation of HIV drug Lenacapavir in India and 120 other countries. The agreement includes technology transfer, bioequivalence/clinical studies, and product registration. Lenacapavir, approved for treatment-experienced adults with multi-drug resistant HIV-1, is also under investigation for HIV prevention (PrEP).

Gilead Sciences announced a licensing deal for lenacapavir, an HIV treatment, with six generics manufacturers to be sold in 120 lower-income countries. Public Citizen and health groups urged Gilead to license through the Medicines Patent Pool for broader access. While the deal improves access for many, it excludes regions like most of South America and maintains Gilead's control over distribution. Licensing through the Medicines Patent Pool could have ensured more equitable access.

Kailera Therapeutics, backed by Atlas Venture, Bain Capital, RTW Investments, and Lyra Capital, emerges with a $400M Series A to develop GLP-1 drugs for obesity and metabolic conditions. Acquired from Jiangsu Hengrui Pharmaceuticals, KAI-9531, targeting GLP-1 and GIP receptors, is in clinical trials for obesity and Type 2 diabetes. Led by CEO Ron Renaud and board chair John Milligan, Kailera aims to advance next-generation treatments for chronic weight management.

Japan's recent approval of Truvada, an HIV drug for treatment and prevention, faces barriers due to its high cost and insufficient public awareness, despite its effectiveness in reducing HIV infection risk.

2Seventy bio halts enrollment in a key multiple myeloma study for its therapy Abecma to save $80 million, aiming for financial break-even next year. Despite this, Abecma shows growth, with U.S. revenue expected to rise 30% in Q3. The decision reflects an improved treatment landscape for newly diagnosed patients, reducing eligible participants.

Illumina welcomed the ECJ's judgment on GRAIL acquisition; Moffitt Cancer Center and AstraZeneca collaborate on cell therapies; Ginkgo Bioworks introduced Ginkgo Automation; UTHealth Houston and OpenAI integrate AI in healthcare; 10x Genomics' platforms used in glioblastoma research; Generate:Biomedicines and Novartis collaborate on protein therapeutics; Firefly Neuroscience advances AI in neuroscience drug development; Scale Bio partners with CZI in the 100 Million Cell Challenge; Oracle launches CancerMPact Treatment Architecture Trends; Verseon's VersAI outperforms Google's AI; MilliporeSigma introduces Mobius ADC Reactor; Gilead and Genesis Therapeutics collaborate on small molecule therapies; Primrose Bio and ExPLoRNA partner on mRNA medicines; UC College of Medicine and Cincinnati Children’s Hospital find new drug discovery methods.